BioLine RX (Israel) Analysis
| BLRX Stock | ILS 1.50 0.10 6.25% |
BioLine RX has over 10.69 Million in debt which may indicate that it relies heavily on debt financing. With a high degree of financial leverage come high-interest payments, which usually reduce BioLine RX's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
BioLine RX's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. BioLine RX's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps BioLine Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect BioLine RX's stakeholders.
For most companies, including BioLine RX, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for BioLine RX, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, BioLine RX's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that BioLine RX's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which BioLine RX is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of BioLine RX to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, BioLine RX is said to be less leveraged. If creditors hold a majority of BioLine RX's assets, the Company is said to be highly leveraged.
BioLine RX is overvalued with Real Value of 1.43 and Hype Value of 1.5. The main objective of BioLine RX stock analysis is to determine its intrinsic value, which is an estimate of what BioLine RX is worth, separate from its market price. There are two main types of BioLine RX's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect BioLine RX's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of BioLine RX's stock to identify patterns and trends that may indicate its future price movements.
The BioLine RX stock is traded in Israel on Tel Aviv Stock Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Sun except for officially observed holidays in Israel. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BioLine RX's ongoing operational relationships across important fundamental and technical indicators.
BioLine |
BioLine Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLine RX recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 7th of June 2015. BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people. For more info on BioLine RX please contact the company at (972) 8 642 9101 or go to www.biolinerx.com.BioLine RX Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. BioLine RX's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding BioLine RX or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| BioLine RX generated a negative expected return over the last 90 days | |
| BioLine RX may become a speculative penny stock | |
| BioLine RX has high historical volatility and very poor performance | |
| Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
BioLine Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 135.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLine RX's market, we take the total number of its shares issued and multiply it by BioLine RX's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 14th of January 2026, BioLine RX shows the Standard Deviation of 4.37, mean deviation of 3.16, and Risk Adjusted Performance of (0.09). BioLine RX technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioLine RX Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Simple Moving Average indicator is calculated by adding the closing price of BioLine RX for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out BioLine RX short-term fluctuations and highlight longer-term trends or cycles.
BioLine RX Outstanding Bonds
BioLine RX issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLine RX uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLine bonds can be classified according to their maturity, which is the date when BioLine RX has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
BioLine RX Predictive Daily Indicators
BioLine RX intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLine RX stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 1.5 | |||
| Day Typical Price | 1.5 | |||
| Price Action Indicator | (0.05) | |||
| Period Momentum Indicator | (0.10) |
BioLine RX Forecast Models
BioLine RX's time-series forecasting models are one of many BioLine RX's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLine RX's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BioLine RX Debt to Cash Allocation
BioLine RX has accumulated 10.69 M in total debt with debt to equity ratio (D/E) of 23.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioLine RX has a current ratio of 5.02, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BioLine RX until it has trouble settling it off, either with new capital or with free cash flow. So, BioLine RX's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLine RX sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLine to invest in growth at high rates of return. When we think about BioLine RX's use of debt, we should always consider it together with cash and equity.BioLine RX Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the BioLine RX's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of BioLine RX, which in turn will lower the firm's financial flexibility.BioLine RX Corporate Bonds Issued
Most BioLine bonds can be classified according to their maturity, which is the date when BioLine RX has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About BioLine Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioLine RX prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioLine shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioLine RX. By using and applying BioLine Stock analysis, traders can create a robust methodology for identifying BioLine entry and exit points for their positions.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding BioLine RX to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |